{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:10:22Z","timestamp":1790698222969,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease (FD) is a rare multi-systemic lysosomal storage disease that affects the heart and kidneys most significantly. An underappreciated manifestation of FD is reduced bone mineral density. Currently, there are no specific guidelines for routine bone density assessments, and treatment of osteoporosis and osteopenia in FD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>To ascertain the frequency of low bone mineral density in FD we studied dual-energy x-ray absorptiometry (DXA) scans obtained as part of routine care from a cohort of 25 individuals followed at the University of California\u2014Irvine Medical Center for the period 2008\u20132023.\u00a0The most recent BMD results for the lumbar spine and femoral neck were collected from 12 males and 13 females to examine the prevalence of low bone mineral density. The lowest Z- and\/or T-scores of either lumbar spine or femoral neck were selected for analysis. Demographic factors, disease and ERT status, and other laboratory values were collected concurrently (within\u2009\u00b1\u20099\u00a0months) with DXA scan results and were analyzed with Z- and T-scores to assess for correlations. In our cohort the mean age was 51\u00a0years (median 56\u00a0years, range 18\u201377\u00a0years). The Z-scores for all participants and T-scores from postmenopausal women and men\u2009\u2265\u200950-year-old were analyzed and correlated with various measures including disease duration, BMI, renal function (measured by eGFR), plasma GL3, Lyso-GL3, calcium, vitamin D, and alkaline phosphatase levels. These parameters were concurrent with DXA scan results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The average Z-score for all the participants was \u22121.2\u2009\u00b1\u20091.3 (range \u22124.6 to 1.6). Twenty-four percent of all participants (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      6) had significantly low Z-scores \u2264\u2009\u22122.0. To identify the frequency of subjects with osteopenia, defined as T-score between \u22121.0 and \u22122.5 and osteoporosis defined as T-score\u2009&lt;\u2009\u22122.5, T-scores were analyzed in postmenopausal women (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      8) and men 50\u00a0years and older (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      7). Of these 15 individuals, average T-score was \u22122.2\u2009\u00b1\u20091.3 (range \u22125.4 to 0.3), and 86.7% (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      13) had abnormal results (osteopenia and osteoporosis), 53.3% (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      8) had osteoporosis and 33.3% (\n                      <jats:italic>n\u2009=\u2009<\/jats:italic>\n                      5) had osteoporosis. We found a significant difference in Z-scores between male (\u22121.98\u2009\u00b1\u20091.33) and female patients (\u2212.45\u2009\u00b1\u20090.82) t (23)\u2009=\u20093.487 (\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      \u2009&lt;\u20090.001). We did not find any differences in z-scores between different ethnic backgrounds.\u00a0There was a strong negative correlation between Z-scores and Lyso-GL3 levels [r (15)\u2009=\u2009\u2212.72,\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      .001] and a moderate positive correlation between Z-scores and body mass index (BMI) [r (23)\u2009=\u2009.43,\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      .033]. No correlation was found between Z-scores and calcium levels. There is a strong negative correlation between T-scores and Lyso-GL3 levels [r (8)\u2009=\u2009-.86,\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      .001] and a negative correlation between T-scores and participants\u2019 ages at the time of DXA [r (13)\u2009=\u2009\u2212.57,\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      0.028]. There is a positive correlation between T- scores and calcium levels [r (12)\u2009=\u2009.58,\n                      <jats:italic>p\u2009=\u2009<\/jats:italic>\n                      0.030]. No significant correlation was observed between T-scores and BMI. There was no correlation between Z or T- scores and disease duration, duration of ERT use, renal function (measured by eGFR), GL3, creatinine, alkaline phosphatase levels, or their use of vitamin D or concomitant antiepileptic medications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this cohort highlight the high prevalence of low bone mineral density in FD and correlations of low Z and T- scores with elevated levels of Lyso-GL3, and low calcium levels. We did not find correlations with renal function, and vitamin D levels. We discuss etiology, prevention, and treatment strategies for osteopenia\/osteoporosis in Fabry disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03601-x","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T19:43:28Z","timestamp":1745955808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Alyaa","family":"Shmara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mania","family":"Mgdsyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Martin-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda E.","family":"Polgreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-4449","authenticated-orcid":false,"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"3601_CR1","unstructured":"Mehta A, Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132024.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/"},{"issue":"7","key":"3601_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/biom11070951","volume":"11","author":"V Gragnaniello","year":"2021","unstructured":"Gragnaniello V, Burlina AP, Polo G, Giuliani A, Salviati L, Duro G, Cazzorla C, Rubert L, Maines E, Germain DP, Burlina AB. Newborn screening for fabry disease in northeastern italy: results of five years of experience. Biomolecules. 2021;11(7):951. https:\/\/doi.org\/10.3390\/biom11070951.","journal-title":"Biomolecules"},{"key":"3601_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100700","volume":"26","author":"M Dutra-Clarke","year":"2021","unstructured":"Dutra-Clarke M, Tapia D, Curtin E, R\u00fcnger D, Lee GK, Lakatos A, Alandy-Dy Z, Freedkin L, Hall K, Ercelen N, Alandy-Dy J, Knight M, Pahl M, Lombardo D, Kimonis V. Variable clinical features of patients with FD and outcome of enzyme replacement therapy. Molecular Genetics and Metabolism Reports. 2021;26: 100700. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100700.","journal-title":"Molecular Genetics and Metabolism Reports"},{"issue":"1","key":"3601_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","volume":"68","author":"DP Germain","year":"2005","unstructured":"Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: Previously unrecognized manifestations of FD. Clin Genet. 2005;68(1):93\u20135. https:\/\/doi.org\/10.1111\/j.1399-0004.2005.00457.x.","journal-title":"Clin Genet"},{"key":"3601_CR5","doi-asserted-by":"publisher","unstructured":"Mersebach, H., Johansson, J.-O., Rasmussen, A. K., Bengtsson, B.-A., Rosenberg, K., Hasholt, L., S\u00f8rensen, S. A., S\u00f8rensen, S. S., & Feldt-Rasmussen, U. (2007). Osteopenia: A common aspect of FD. Predictors of bone mineral density. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 9(12), 812\u2013818. https:\/\/doi.org\/10.1097\/gim.0b013e31815cb197","DOI":"10.1097\/gim.0b013e31815cb197"},{"issue":"3","key":"3601_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab. 2010;100(3):257\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2010.03.020.","journal-title":"Mol Genet Metab"},{"key":"3601_CR7","doi-asserted-by":"publisher","unstructured":"Talbot, A., Ghali, J. R., & Nicholls, K. (2014). Antiepileptic Medications Increase Osteoporosis Risk in Male Fabry Patients: Bone Mineral Density in an Australian Cohort. In J. Zschocke, K. M. Gibson, G. Brown, E. Morava, & V. Peters (Eds.), JIMD Reports, Volume 17 (Vol. 17, pp. 29\u201336). Springer Berlin Heidelberg. https:\/\/doi.org\/10.1007\/8904_2014_328","DOI":"10.1007\/8904_2014_328"},{"issue":"4","key":"3601_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107634","volume":"139","author":"Y Nose","year":"2023","unstructured":"Nose Y, Fujii H, Goto S, Kono K, Okamoto H, Watanabe K, Nishi S. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease. Mol Genet Metab. 2023;139(4): 107634. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107634.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3601_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11914-996-0016-3","volume":"3","author":"EM Lewiecki","year":"2005","unstructured":"Lewiecki EM. Update on bone density testing. Curr Osteoporos Rep. 2005;3(4):136\u201342. https:\/\/doi.org\/10.1007\/s11914-996-0016-3.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"3601_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/BF00296209","volume":"51","author":"R Mazess","year":"1992","unstructured":"Mazess R, Chesnut CH, McClung M, Genant H. Enhanced precision with dual-energy X-ray absorptiometry. Calcif Tissue Int. 1992;51(1):14\u20137. https:\/\/doi.org\/10.1007\/BF00296209.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"3601_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0969-8043(98)00026-8","volume":"50","author":"CF Njeh","year":"1999","unstructured":"Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK. Radiation exposure in bone mineral density assessment. Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine. 1999;50(1):215\u201336. https:\/\/doi.org\/10.1016\/s0969-8043(98)00026-8.","journal-title":"Applied radiation and isotopes: including data, instrumentation and methods for use in agriculture, industry and medicine"},{"issue":"4","key":"3601_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1115\/1.2895412","volume":"113","author":"JC Lotz","year":"1991","unstructured":"Lotz JC, Cheal EJ, Hayes WC. Fracture prediction for the proximal femur using finite element models: Part I-Linear analysis. J Biomech Eng. 1991;113(4):353\u201360. https:\/\/doi.org\/10.1115\/1.2895412.","journal-title":"J Biomech Eng"},{"issue":"7041","key":"3601_CR13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (Clinical research ed). 1996;312(7041):1254\u20139. https:\/\/doi.org\/10.1136\/bmj.312.7041.1254.","journal-title":"BMJ (Clinical research ed)"},{"issue":"6","key":"3601_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","volume":"43","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43(6):1115\u201321. https:\/\/doi.org\/10.1016\/j.bone.2008.08.106.","journal-title":"Bone"},{"key":"3601_CR15","doi-asserted-by":"publisher","unstructured":"Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., Grams, M. E., Greene, T., Grubb, A., Gudnason, V., Guti\u00e9rrez, O. M., Kalil, R., Karger, A. B., Mauer, M., Navis, G., Nelson, R. G., \u2026 Chronic Kidney Disease Epidemiology Collaboration (2021). New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.\u00a0The New England journal of medicine,\u00a0385(19), 1737\u20131749. https:\/\/doi.org\/10.1056\/NEJMoa2102953","DOI":"10.1056\/NEJMoa2102953"},{"issue":"11","key":"3601_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/iub.257","volume":"61","author":"PA Rozenfeld","year":"2009","unstructured":"Rozenfeld PA. FD: treatment and diagnosis. IUBMB Life. 2009;61(11):1043\u201350. https:\/\/doi.org\/10.1002\/iub.257.","journal-title":"IUBMB Life"},{"issue":"Suppl 2","key":"3601_CR17","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1079\/BJNBJN\/2002534","volume":"87","author":"KD Cashman","year":"2002","unstructured":"Cashman KD. Calcium intake, calcium bioavailability and bone health. Br J Nutr. 2002;87(Suppl 2):S169\u201377. https:\/\/doi.org\/10.1079\/BJNBJN\/2002534.","journal-title":"Br J Nutr"},{"key":"3601_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00198-022-06420-z","volume":"33","author":"S Bruell","year":"2022","unstructured":"Bruell S, Nicholls K, Hewitson T, et al. Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with FD. Osteoporos Int. 2022;33:1783\u201394. https:\/\/doi.org\/10.1007\/s00198-022-06420-z.","journal-title":"Osteoporos Int"},{"issue":"6","key":"3601_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1096\/fba.2019-00080","volume":"2","author":"H Maruyama","year":"2020","unstructured":"Maruyama H, Taguchi A, Mikame M, Lu H, Tada N, Ishijima M, Kaneko H, Kawai M, Goto S, Saito A, Ohashi R, Nishikawa Y, Ishii S. Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg (CAG-A4GALT) mouse model of FD. FASEB bioAdvances. 2020;2(6):365\u201381. https:\/\/doi.org\/10.1096\/fba.2019-00080.","journal-title":"FASEB bioAdvances"},{"issue":"3","key":"3601_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40519-018-0505-2","volume":"23","author":"A Fassio","year":"2018","unstructured":"Fassio A, Idolazzi L, Rossini M, Gatti D, Adami G, Giollo A, Viapiana O. The obesity paradox and osteoporosis. Eating and weight disorders: EWD. 2018;23(3):293\u2013302. https:\/\/doi.org\/10.1007\/s40519-018-0505-2.","journal-title":"Eating and weight disorders: EWD"},{"issue":"2","key":"3601_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2019.10.010","volume":"129","author":"PA Rozenfeld","year":"2020","unstructured":"Rozenfeld PA, de Los Angeles Bolla, M., Quieto, P., Pisani, A., Feriozzi, S., Neuman, P., & Bondar, C. Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis. Mol Genet Metab. 2020;129(2):132\u201341. https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.010.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"3601_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10067-015-2883-4","volume":"34","author":"LG Schipper","year":"2015","unstructured":"Schipper LG, Fleuren HW, van den Bergh JP, Meinardi JR, Veldman BA, Kramers C. Treatment of osteoporosis in renal insufficiency. Clin Rheumatol. 2015;34(8):1341\u20135. https:\/\/doi.org\/10.1007\/s10067-015-2883-4.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3601_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","volume":"137","author":"C T\u00f8ndel","year":"2022","unstructured":"T\u00f8ndel C, Thurberg BL, DasMahapatra P, Lyn N, Maski M, Batista JL, George K, Patel H, Hariri A. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. Mol Genet Metab. 2022;137(4):328\u201341. https:\/\/doi.org\/10.1016\/j.ymgme.2022.10.005.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3601_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00467-023-06050-5","volume":"39","author":"J Avarappattu","year":"2024","unstructured":"Avarappattu J, Gaspert A, Spart\u00e0 G, Rohrbach M. Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease. Pediatric nephrology (Berlin, Germany). 2024;39(1):131\u201340. https:\/\/doi.org\/10.1007\/s00467-023-06050-5.","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"issue":"4","key":"3601_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1155\/2001\/768501","volume":"6","author":"A Kjellgren","year":"2001","unstructured":"Kjellgren A, Sundequist U, Norlander T, Archer T. Effects of flotation-REST on muscle tension pain. Pain Res Manage. 2001;6(4):181\u20139. https:\/\/doi.org\/10.1155\/2001\/768501.","journal-title":"Pain Res Manage"},{"key":"3601_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bone.2015.12.057","volume":"87","author":"D Grimm","year":"2016","unstructured":"Grimm D, Grosse J, Wehland M, Mann V, Reseland JE, Sundaresan A, Corydon TJ. The impact of microgravity on bone in humans. Bone. 2016;87:44\u201356. https:\/\/doi.org\/10.1016\/j.bone.2015.12.057.","journal-title":"Bone"},{"key":"3601_CR27","unstructured":"FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab).\u00a0FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease (2024)."},{"issue":"10","key":"3601_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2013;28(10):2049\u201359. https:\/\/doi.org\/10.1002\/jbmr.2058.","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"3601_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115581","volume":"141","author":"BS Zemel","year":"2020","unstructured":"Zemel BS, Wasserman H, Kelly A, Fan B, Shepherd J, Lappe J, Gilsanz V, Oberfield S, Winer KK, Kalkwarf HJ. Intermachine differences in DXA measurements vary by skeletal site, and impact the assessment of low bone density in children. Bone. 2020;141: 115581. https:\/\/doi.org\/10.1016\/j.bone.2020.115581.","journal-title":"Bone"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03601-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:28:08Z","timestamp":1746505688000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03601-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3601"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03601-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4360683\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided written informed consent for the IRB approved study at the University of California, Irvine (HS#2008\u20136631).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate"}},{"value":"Written informed consent was obtained from all the subjects included in the study. In the case of deceased patients, they provided their consents prior to their demise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VK is the Principal Investigator for the Rare Diseases Sanofi Registry at UC Irvine, CA. VK also receives funding for an outreach education program for FD. Co-authors GL, AMR and AS received fellowship funding from Sanofi.\u00a0LEP\u00a0has received research grants\/contracts from BioMarin, Takeda, Sobi, and Pfizer, consulting fees from BioMarin and Denali, and honorarium and speaker fees from BioMarin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}